Insmed Inc. sell klostergang
Start price
05.09.17
/
50%
€23.52
Target price
29.12.17
€16.24
Performance (%)
20.60%
End price
29.12.17
€28.36
Summary
This prediction ended on 29.12.17 with a price of €28.36. The prediction closed with a disappointing performance of 20.60%. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Insmed Inc. | -6.012% | -6.012% | 88.623% | 576.824% |
| iShares Core DAX® | -1.741% | 5.666% | 7.839% | 50.715% |
| iShares Nasdaq 100 | 2.815% | 11.547% | 36.610% | 102.822% |
| iShares Nikkei 225® | -0.109% | 9.654% | 45.650% | 64.795% |
| iShares S&P 500 | 0.966% | 7.240% | 26.969% | 70.251% |
Comments by klostergang for this prediction
In the thread Insmed Inc. diskutieren
klostergang stimmt der Sell-Einschätzung von kyron7htx zu
The open-label design of the Phase 3 trial will likely have a negative impact on secondary outcomes and may hinder the robustness of Insmed's NDA.
(Vom Mitglied beendet)